3-Ethoxy-4-(3-methylbutan-2-ylamino)cyclobut-3-ene-1,2-dione | 959784-83-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-Ethoxy-4-(3-methylbutan-2-ylamino)cyclobut-3-ene-1,2-dione
• 英文别名: 3-ethoxy-4-(3-methylbutan-2-ylamino)cyclobut-3-ene-1,2-dione
• CAS: 959784-83-9
• 化学式: C₁₁H₁₇NO₃
• 分子量: 211.261
• InChiKey: BRVCKKGGAIPOMR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-Ethoxy-4-(3-methylbutan-2-ylamino)cyclobut-3-ene-1,2-dione 、 2-N-(4-phenylphenyl)pyrimidine-2,4-diamine 在 sodium ethanolate 作用下， 以 二甲基亚砜 为溶剂， 生成 3-(3-Methylbutan-2-ylamino)-4-[[2-(4-phenylanilino)pyrimidin-4-yl]amino]cyclobut-3-ene-1,2-dione
  参考文献：
  名称：

  Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors

  摘要：

  A high throughput screening (HTS) hit, 1 (Plk1 K-i = 2.2 mu M) was optimized and evaluated for the enzymatic inhibition of Plk-1 kinase. Molecular modeling suggested the importance of adding a hydrophobic aromatic amine side chain in order to improve the potency by a classic kinase H-donor-acceptor binding mode. Extensive SAR studies led to the discovery of 49 (Plk1 K-i = 5 nM; EC50 = 1.05 mu M), which demonstrated moderate efficacy at 100 mpk in a MiaPaCa tumor model, with no overt toxicity. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.009
• 作为产物：
  描述：

  1,2-甲基丙胺 、 方酸二乙酯 以 乙醇 为溶剂， 生成 3-Ethoxy-4-(3-methylbutan-2-ylamino)cyclobut-3-ene-1,2-dione
  参考文献：
  名称：

  Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors

  摘要：

  A high throughput screening (HTS) hit, 1 (Plk1 K-i = 2.2 mu M) was optimized and evaluated for the enzymatic inhibition of Plk-1 kinase. Molecular modeling suggested the importance of adding a hydrophobic aromatic amine side chain in order to improve the potency by a classic kinase H-donor-acceptor binding mode. Extensive SAR studies led to the discovery of 49 (Plk1 K-i = 5 nM; EC50 = 1.05 mu M), which demonstrated moderate efficacy at 100 mpk in a MiaPaCa tumor model, with no overt toxicity. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.009

文献信息

• [EN] CYCLOBUTENEDIONE DERIVATIVES<br/>[FR] DÉRIVÉS DE CYCLOBUTÈNE-DIONE
  申请人：PFIZER LTD

  公开号：WO2010131145A1

  公开（公告）日：2010-11-18

  The present invention relates to compounds of the formula (I): to pharmaceutically acceptable salts therefore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly inflammatory conditions.

  本发明涉及以下式(I)的化合物：以及其药学上可接受的盐和所述化合物及盐的药学上可接受的溶剂化物，其中取代基在此处定义；含有这种化合物的组合物；以及这种化合物在治疗各种疾病，特别是炎症性疾病中的用途。
• WO2007/140233
  申请人：——

  公开号：——

  公开（公告）日：——